SCHEMBL5264263

SCHEMBL5264263

Cc1ccn2c(-c3ccc([S+](C)[O-])cc3)c(-c3ccc(F)cc3)nc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.50
MAPK13 O15264 5/20 0.50
MAPK12 P53778 5/20 0.50
MAPK11 Q15759 5/20 0.50
AKT1 P31749 5/20 0.49
AKT2 P31751 5/20 0.49
PTGS2 P35354 2/20 0.39
PTGS1 P23219 1/20 0.39
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
FGFR1 P11362 1/20 0.38
FRK P42685 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
CSNK1A1 P48729 1/20 0.38
CSNK1D P48730 1/20 0.38
GSK3B P49841 1/20 0.38
CSNK1G2 P78368 1/20 0.38
PRKCD Q05655 1/20 0.38
ERBB4 Q15303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5265191 0.89 AKT1 (0.61) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5262246 0.89 AKT1 (0.61) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5265058 0.88 AKT1 (0.49) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5261530 0.86 AKT1 (0.47) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5261484 0.84 AKT1 (0.48) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5261444 0.83 MAPK14 (0.42) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5261876 0.82 ALDH1A1 (0.41) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5266214 0.81 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5263237 0.81 AKT1 (0.43) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5263130 0.81 AKT1 (0.43) MAPK14AKT1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660500-B1 SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER S A L V A T LAB SA (ES) 2007-12-12 EP disclosed
US-20060189631-A1 Substituted imidazopyrimidines for the prevention and treatment of cancer LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189631-A1 Substituted imidazopyrimidines for the prevention and treatment of cancer BRCA1, CCNA1, DPYD MAPK14 3719/4885MAPK13 3002/4885MAPK12 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.